NASDAQ: RADXRadiopharm Theranostics Ltd Stock
$4.37+0.12 (+2.82%)
Updated Jul 2, 2026
RADX Price
$4.37
Fair Value Price
N/A
Market Cap
$31.00M
52 Week Low
$3.62
52 Week High
$16.25
P/E
-1.27x
P/B
1.06x
P/S
14.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.37M
Earnings
-$23.84M
Gross Margin
1.1%
Operating Margin
-992.74%
Profit Margin
-997.4%
Debt to Equity
0.97
Operating Cash Flow
-$24M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RADX Overview
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RADX's potential to beat the market
- RADX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RADX
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important RADX news, forecast changes, insider trades & much more!
RADX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RADX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RADX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RADX is good value based on its book value relative to its share price (1.06x), compared to the US Biotechnology industry average (5.6x)
P/B vs Industry Valuation
RADX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RADX due diligence checks available for Premium users.
Valuation
RADX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.27x
Industry
17.59x
Market
8.54x
RADX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.06x
Industry
5.6x
RADX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RADX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RADX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RADX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$56.9M
Liabilities
$28.7M
Debt to equity
0.97
RADX's short-term assets ($26.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RADX's short-term assets ($26.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RADX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
RADX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RADX vs Biotech Stocks
Radiopharm Theranostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.